Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9. (Q40221792)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

0 references

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Chi-Ping Chan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Kit-San Yuen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Nok-Hei Mickey Wong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Zhi-Qian Zhang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Tsz-Fung Cheng

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Wai-Yin Lui

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Dong-Yan Jin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

27 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

244

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

296-303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

High-efficiency targeted editing of large viral genomes by RNA-guided nucleases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Multiplex genome engineering using CRISPR/Cas systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Gene therapy for lipoprotein lipase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Epstein-Barr virus infections: prospects for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Epstein-barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Suppression of EBNA1 expression inhibits growth of EBV-positive NK/T cell lymphoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Targeting hepatitis B virus cccDNA using CRISPR/Cas9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

EBV DNA polymerase inhibition of tannins from Eugenia uniflora

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Targeting of DICE1 tumor suppressor by Epstein-Barr virus-encoded miR-BART3* microRNA in nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

The pathological roles of BART miRNAs in nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Antigen-specific T cell therapies for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Epstein-Barr virus in the pathogenesis of NPC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Novel mechanisms of EBV-induced oncogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Antiviral treatment for severe EBV infections in apparently immunocompetent patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Genome engineering using the CRISPR-Cas9 system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Analyzing real-time PCR data by the comparative C(T) method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Targeting Hepatitis B Virus With CRISPR/Cas9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Genome-scale CRISPR-Cas9 knockout screening in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Epstein-Barr virus particles induce centrosome amplification and chromosomal instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

The role of Epstein-Barr virus in epithelial malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Complete genomic sequence of Epstein-Barr virus in nasopharyngeal carcinoma cell line C666-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates polymerase η recruitment to DNA damage sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Epidemiology of nasopharyngeal carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2017.04.019

10.1016/J.VIRUSRES.2017.04.019

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28456574%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference